The CAR T-cell therapy for multiple myeloma pipeline analysis report includes ongoing clinical and non-clinical trends in the global CAR T-cell therapy for multiple myeloma.
Most of the pipeline therapeutics are in early stages of development; there is no CAR T-cell therapy approved to date for multiple myeloma treatment, but other treatments are available. A long-lasting and less-frequent dose can impact the overall multiple myeloma market.
In recent past, many pilot studies and early clinical trials have shown very promising results in the treatment of multiple myeloma with CAR T-cell therapy. However, the market has yet to witness the approval of the first CAR T-cell therapy for multiple myeloma, and it may take a few years from now. The currently available treatment for multiple myeloma include chemotherapy and other drugs, bisphosphonates, radiation, surgery, stem cell transplant, and plasmapheresis.
According to the National Cancer Institute (NIH), in 2017, there will be 30,280 new cases of myeloma and an estimated 12,590 deaths occur due to this disease in the US.
Covered in this report
The report covers the present scenario and the growth prospects of the car T-cell therapy for multiple myeloma. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
Technavio's CAR T-cell Therapy for Multiple Myeloma – A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
- Juno Therapeutics
- Kite Pharma
- How will the market evolve during the forecast period?
- What are the major parameters impacting the market?
- What are the key market trends?
- What are the challenges to market growth?
- Who are the key companies in this market space?
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR MULTIPLE MYELOMA: AN INSIGHT
PART 07: COMPARATIVE ANALYSIS
- Mid-stage molecules (Phase II and I/II)
- Early-stage molecules (Phase I and IND)
- Pre-clinical and discovery-stage molecules
PART 09: THERAPEUTIC ASSESSMENT BY THERAPY
- Therapeutic assessment based on therapy
- Therapeutic assessment based on RoA
PART 12: KEY COMPANIES
- Active companies: Category and parameters
- List of abbreviations
Exhibit 01: Drug approval process by US FDA
Exhibit 02: Pipeline molecules by vendors
Exhibit 03: Pipeline landscape
Exhibit 04: Pipeline molecules by numbers
Exhibit 05: Pipeline molecules by percentage
Exhibit 06: Overview: Tisagenlecleucel-T
Exhibit 07: Clinical Trials Description of Tisagenlecleucel-T (CTL019 T-cells)
Exhibit 08: Overview: LCAR-B38M
Exhibit 09: Clinical trials description
Exhibit 10: Overview: AUTO2
Exhibit 11: Clinical trials description of AUTO2
Exhibit 12: P-BCMA-101: Overview
Exhibit 13: Overview: CAR-T NKR-2
Exhibit 14: Clinical trials description of CAR-T NKR-2
Exhibit 15: Overview: CM-CS1
Exhibit 16: Clinical trials description of CM-CS1
Exhibit 17: Overview: EGFRt/BCMA-41BBz CAR T-cell
Exhibit 18: Clinical trials description of EGFRt/BCMA-41BBz CAR T-cell
Exhibit 19: Overview: bb2121
Exhibit 20: Clinical trials description of bb2121
Exhibit 21: Overview: KITE-585
Exhibit 22: Overview: T-007
Exhibit 23: Overview: KMA.CAR-T
Exhibit 24: Overview: MB-104 CS1 CAR
Exhibit 25: Overview: Compound CAR
Exhibit 26: Overview: UCART38
Exhibit 27: Overview: UCARTCS1
Exhibit 28: Overview: LMA.CAR-T
Exhibit 29: Analysis by indication
Exhibit 30: Overview of indication
Exhibit 31: Assessment of pipeline products by therapy
Exhibit 32: Assessment by RoA
Exhibit 33: Assessment by target
Exhibit 34: Percentage of the company for different tier category
Exhibit 35: Overview: Autolus 2017
Exhibit 36: Overview: bluebird bio 2017
Exhibit 37: Overview: Celyad 2016
Exhibit 38: Overview: Cellectis 2016
Exhibit 39: Overview: HaemaLogiX 2017
Exhibit 40: Overview: iCell Gene Therapeutics 2017
Exhibit 41: Overview: Juno Therapeutics 2017
Exhibit 42: Overview: Kite Pharma 2017
Exhibit 43: Overview: Mustang Bio 2017
Exhibit 44: Overview: Nanjing Legend Biotech 2017
Exhibit 45: Overview: Novartis 2017
Exhibit 46: Overview: Poseida 2017
Exhibit 47: Overview: TNK Therapeutics 2016
The author of the report recognizes the following companies in the car T-cell therapy for multiple myeloma: Juno Therapeutics, Kite Pharma, Novartis, and Collectis.
The “Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma - A pipeline analysis report, 2017”, provides comprehensive insights about pipeline molecules across this approach of treatment. The key objective of the report is to establish the understanding of all the pipeline molecules that fall under CAR T-cell therapy for multiple myeloma.
This report provides information on the therapeutic development based on the CAR T-cell therapy for multiple myeloma dealing with all the pipeline drugs; comparative analysis at various stages covering Phase III, Phase II, Phase I/II, and pre-clinical; therapeutics assessment by monotherapy and combination products; and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products. It also highlights the dormant products.
CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. They are engineered receptors, which graft an arbitrary specificity onto an immune effector cell (T-cell). CAR T-cell therapy uses an individual's own cells and “re-engineers” them to fight cancer. It is a very complex treatment.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.